Therefore, this research aims to evaluate the differences in total antioxidant capacity (TAC), oxidative damage markers (malondialdehyde [MDA] and carbonylated proteins [CP]), and angiogenic (sFlt-1, PlGF) and RAS (ANG-II, ACE-2) markers in pregnant women with severe and non-severe COVID-19. This evidence concerns the gene ACE2 and COVID-19.